Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-04-05

Clinical Trial Update: Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes [Phase 3]

View source ↗

Summary

Phase 3 trial comparing Fasiglifam (TAK-875) to placebo in adults with type 2 diabetes; results were posted in April 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Fasiglifam (TAK-875) (fasiglifam)

Snippet

Sponsor: Takeda | Conditions: Diabetes Mellitus, Type 2 | Phase 3 | Status: COMPLETED | Results posted: 2016-04-05